Effective May 20, 2019, Spectrum Health Regional Laboratory Cytogenetics Department is pleased to announce the launch of a new microarray platform AffymetrixTM Cytoscan® HD. The Affymetrix Cytoscan HD is designed for the accurate and comprehensive analysis of chromosomal variants in the human genome.
Effective January 19, 2019, Spectrum Health Regional Laboratory – Toxicology is proud to announce the availability of two new drug screen panels:
- LAB1230496 – Urine Drug Screen with Confirmation (23 Targets)
- LAB1230497 – Urine Drug Screen with Confirmation (32 Targets)
This new lateral flow immunochromatographic test offers enhanced sensitivity through the detection of Trichomonas antigen as opposed to the traditional wet prep method, which relied on the labor intensive microscopic visualization of motile Trichomonas trophozoites. Because this new assay detects antigen as opposed to viable organism, specimen stability is also extended. When collected with a single eSwab™, specimens are stable for up to 24 hours at ambient temperature and 36 hours when refrigerated. Swabs collected for the wet prep method were only stable for 3-5 hours, so there is no longer a need for STAT delivery to the laboratory.
The treatment of non-small cell lung adenocarcinoma has become more successful due to targeted treatments based on the molecular profile of a patient’s particular tumor. The Lung Cancer Mutation Analysis panel is now available for clinical testing at the Spectrum Health Advanced Technology Laboratories (ATL).